You are here

ALS

5 years later, Ice Bucket Challenge's impact on drug research still unfolding

5 years later, Ice Bucket Challenge's impact on drug research still unfolding

Bizjournals

drug development

Flag link:

In another disappointment for investors, FDA slaps down Biohaven’s revised version of an old ALS drug

In another disappointment for investors, FDA slaps down Biohaven’s revised version of an old ALS drug

Endpoints

Flag link:

Mallinckrodt Halts Midstage ALS Trial Over Safety Concerns

Mallinckrodt Halts Midstage ALS Trial Over Safety Concerns

BioSpace

clinical trials

H.P. Acthar Gel

Flag link:

Biogen’s Experimental Drug Shows Promise for Genetic Form of ALS

Biogen’s Experimental Drug Shows Promise for Genetic Form of ALS

BioSpace

Ionis Pharmaceuticals

Flag link:

Cytokinetics' comeback attempt with second-gen drug is slammed by a PhII failure in ALS

Cytokinetics' comeback attempt with second-gen drug is slammed by a PhII failure in ALS

Endpoints

clinical trials

Flag link:

Biogen’s antisense ALS drug shows promise in early clinical trial

Biogen’s antisense ALS drug shows promise in early clinical trial

Fierce Biotech

clinical trials

Flag link:

Research Roundup: New CRISPR, ALS, Colon Cancer, Asthma and More

Research Roundup: New CRISPR, ALS, Colon Cancer, Asthma and More

BioSpace

Flag link:

ALS researchers at Harvard uncover new biomarker and drug target

ALS researchers at Harvard uncover new biomarker and drug target

Fierce Biotech

Lou Gehrig's disease

Flag link:

Biogen opts in for Ionis' ALS candidate, plans pivotal trial

Biogen opts in for Ionis' ALS candidate, plans pivotal trial

BioCentury

Ionis Pharmaceuticals

Flag link:

Researchers Cure ALS in Laboratory Animals Using Gene Therapy

Researchers Cure ALS in Laboratory Animals Using Gene Therapy

BioSpace

Lou Gehrig's disease

University of California

Flag link:

PARP inhibitors show promise for treating ALS and other brain disorders

PARP inhibitors show promise for treating ALS and other brain disorders

Fierce Biotech

PARP inhibitors

Flag link:

Orion takes repurposed heart failure drug into phase 3 for ALS

Orion takes repurposed heart failure drug into phase 3 for ALS

Fierce Biotech

clinical trials

Flag link:

ALS drug maker walks back plan to profit from right-to-try law following heavy criticism

ALS drug maker walks back plan to profit from right-to-try law following heavy criticism

Stat

BrainStorm Cell Therapeutics

right-to-try laws

clinical trials

Flag link:

Step right up: A biotech may soon sell an experimental med to dying ALS patients under ‘Right to Try’

Step right up: A biotech may soon sell an experimental med to dying ALS patients under ‘Right to Try’

Endpoints

right-to-try laws

BrainStorm Cell Therapeutics

Flag link:

Flex Pharma dumps midstage trials, cuts workforce, mulls a sale to stay alive

Flex Pharma dumps midstage trials, cuts workforce, mulls a sale to stay alive

Fierce Biotech

Flag link:

QurAlis Announces New Investors to Help Fund Drive to Cure ALS

QurAlis Announces New Investors to Help Fund Drive to Cure ALS

CP Wire

Flag link:

QurAlis Announces New Investors to Help Fund Drive to Cure ALS

Flag link:

Sangamo shares surge 3.4% on $12 mln ALS gene therapy collaboration with Pfizer

Sangamo shares surge 3.4% on $12 mln ALS gene therapy collaboration with Pfizer

Marketwatch

drug development

Flag link:

New target could yield treatment for Alzheimer's, ALS and more

New target could yield treatment for Alzheimer's, ALS and more

Fierce Biotech

drug development

Alzheimer's disease

Flag link:

The First ALS Drug In 22 Years Is Approved -- And It Costs 4 Times What It Does In Japan

The First ALS Drug In 22 Years Is Approved -- And It Costs 4 Times What It Does In Japan

Forbes

Flag link:

Pages